News | March 06, 2014

First Patient Enrolled in Lipid-Rich Plaque Study

Testing near-infrared coronary imaging ability to predict heart attack risk

Infraredx Inc. TVC Imaging System Intravascular Ultrasound IVUS Clinical Study

March 6, 2014 — MedStar Heart Institute of Washington, D.C., and Infraredx Inc. enrolled the first participant in the Lipid-Rich Plaque (LRP) Study. The LRP Study is a prospective, multi-center study aimed at identifying a correlation between LRPs and the occurrence of a cardiac event within two years. LRPs, which are implicated in most heart attacks, will be identified in study participants using the Infraredx TVC Imaging System, a dual modality intravascular imaging catheter.

MedStar Heart Institute is one of the 100 clinical sites worldwide to participate in the trial. 

“We are pleased to announce the start of enrollment for this major international study testing the ability of near-infrared spectroscopy (NIRS) to detect the cholesterol-rich plaques suspected of causing heart attacks,” said James Muller, M.D., co-founder and chief medical officer of Infraredx. “The decision to undertake this important study was based on a wealth of data stemming from decades of research and development by a dedicated team of more than 100 engineers and clinical scientists. Once completed, the LRP Study could redefine the role of intravascular imaging and lay the groundwork for changing standard protocol for managing coronary artery disease.”

The TVC Imaging System integrates NIRS to detect lipid-core plaques, and enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, including the presence of plaques and the degree of stenosis. The system identifies plaques suspected to be vulnerable to rupture, which can cause a fatal coronary blockage. Current methods of diagnosing coronary artery disease are limited in their ability to detect such plaques.

Previous studies have demonstrated that NIRS imaging in patients can identify cholesterol-rich plaques that have caused a heart attack or cardiac arrest. In a heart attack study published in the Journal of the American College of Cardiology Cardiovascular Interventions, researchers used NIRS imaging to detect a lipid-rich plaque at the culprit site in 19 of the 20 patients studied. This data was featured as one of Discover magazine’s top 100 science stories of 2013.

“The LRP Study could be the largest study to use intravascular imaging to link suspected vulnerable plaques to a higher risk of future coronary events.” said Ron Waksman, M.D., international principal investigator of the LRP Study, and director of cardiovascular research and advanced education at the MedStar Heart Institute. “Successful identification of vulnerable plaques could help clinicians better manage high-risk patients and potentially prevent coronary events with the vast array of currently available interventional devices.”

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init